Roux‐en‐Y probably leads to lower incidence of bile reflux compared with billroth‐I after distal gastrectomy (moderate certainty).
Roux‐en‐Y may leads to higher postoperative morbidity compared with billroth‐I after distal gastrectomy (low certainty).
It is very uncertain whether more frequent (less than eight hours) changes mortality (at the end of compared with less frequent (eight hours or greater) monitoring of gastric… (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether more frequent (less than eight hours) changes pneumonia (until discontinued or up to 28 days) compared with less frequent (eight hours or greater) monitoring of gastric… (very low certainty).
It is very uncertain whether no monitoring changes mortality (at the end of compared with frequent monitoring (12 hours or less) of gastric residual volume (very low certainty).
It is very uncertain whether no monitoring changes pneumonia (until discontinued or up to 28 days) compared with frequent monitoring (12 hours or less) of gastric residual volume (very low certainty).
It is very uncertain whether higher threshold (500 mL per six hours or greater) changes mortality (at the end of compared with lower threshold (less than 500 mL per six hours) at time of aspiration (very low certainty).
It is very uncertain whether higher threshold (500 mL per six hours or greater) changes pneumonia (until discontinued or up to 28 days) compared with lower threshold (less than 500 mL per six hours) at time of aspiration (very low certainty).
IV iron sucrose showed no clear difference in number of responders ‐ active or inactive disease (6 weeks) compared with oral iron sulphate (low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
Oral ferric maltol showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV ferric carboxymaltose (low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
IV ferric carboxymaltose showed no clear difference in number of responders ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (low certainty).